Vor Biopharma (NYSE:VOR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Vor Biopharma and Nuvation Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Vor Biopharma | 1 | 0 | 4 | 0 | 2.60 |
Nuvation Bio | 0 | 0 | 6 | 0 | 3.00 |
Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 73.48%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Vor Biopharma.
Earnings and Valuation
This table compares Vor Biopharma and Nuvation Bio's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Vor Biopharma | N/A | N/A | N/A | N/A | N/A |
Nuvation Bio | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Vor Biopharma and Nuvation Bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Vor Biopharma | N/A | N/A | N/A |
Nuvation Bio | N/A | N/A | N/A |
Summary
Nuvation Bio beats Vor Biopharma on 3 of the 3 factors compared between the two stocks.